Literature DB >> 33440683

Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy.

Carmelo Gurnari1,2,3,4, Maria Teresa Voso2,5, Katia Girardi1, Angela Mastronuzzi1, Luisa Strocchio1.   

Abstract

Acute promyelocytic leukemia (APL) represents a paradigm of precision medicine. Indeed, in the last decades, the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) completely revolutionized the therapeutic approach to this previously highly fatal disorder. This entirely chemotherapy-free treatment, which provided excellent survival rates, has been initially validated in adults and, recently, translated in the pediatric setting. This review summarizes currently available data on the use of ATRA and ATO combination in pediatric APL, providing a particular focus on peculiar issues and challenges, such as the occurrence of pseudotumor cerebri and death during induction (early death), as well as the advantage offered by the ATO/ATRA combination in sparing long-term sequelae.

Entities:  

Keywords:  acute promyelocytic leukemia; all-trans retinoic acid; arsenic trioxide; children

Mesh：

Year:  2021        PMID： 33440683      PMCID： PMC7826974          DOI： 10.3390/ijms22020642

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  85 in total

1.  Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.

Authors:  Luisa Strocchio; Carmelo Gurnari; Nicola Santoro; Maria C Putti; Concetta Micalizzi; Marco Zecca; Rosanna Cuccurullo; Katia Girardi; Daniela Diverio; Anna M Testi; Francesco Lo-Coco; Franco Locatelli
Journal:  Br J Haematol       Date:  2018-07-20       Impact factor: 6.998

2.  Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.

Authors:  Madhvi Rajpurkar; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Alan S Gamis; James H Feusner; John Gregory; Matthew A Kutny
Journal:  J Pediatr Hematol Oncol       Date:  2019-01       Impact factor: 1.289

Review 3.  Understanding the molecular pathogenesis of acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Syed Khizer Hasan
Journal:  Best Pract Res Clin Haematol       Date:  2014-04-13       Impact factor: 3.020

4.  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

Authors:  M A Sanz; F Lo Coco; G Martín; G Avvisati; C Rayón; T Barbui; J Díaz-Mediavilla; G Fioritoni; J D González; V Liso; J Esteve; F Ferrara; P Bolufer; C Bernasconi; M Gonzalez; F Rodeghiero; D Colomer; M C Petti; J M Ribera; F Mandelli
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

5.  Advances in the management of coagulopathy in acute promyelocytic leukemia.

Authors:  Miguel A Sanz; Pau Montesinos
Journal:  Thromb Res       Date:  2020-07       Impact factor: 3.944

6.  PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Authors:  L Cicconi; M Divona; C Ciardi; T Ottone; A Ferrantini; S Lavorgna; V Alfonso; F Paoloni; A Piciocchi; G Avvisati; F Ferrara; E Di Bona; F Albano; M Breccia; E Cerqui; M Sborgia; M G Kropp; A Santoro; A Levis; S Sica; S Amadori; M T Voso; F Mandelli; F Lo-Coco
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

7.  Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.

Authors:  Carmelo Gurnari; Massimo Breccia; Francesca Di Giuliano; Emilia Scalzulli; Mariadomenica Divona; Alfonso Piciocchi; Laura Cicconi; Eleonora De Bellis; Adriano Venditti; Maria Ilaria Del Principe; William Arcese; Francesco Lo-Coco; Francesco Garaci; Maria Teresa Voso
Journal:  Br J Haematol       Date:  2020-08-10       Impact factor: 6.998

8.  Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells.

Authors:  Colin Kwok; Bernd B Zeisig; Shuo Dong; Chi Wai Eric So
Journal:  Cancer Cell       Date:  2006-02       Impact factor: 31.743

9.  Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism.

Authors:  Luca Mazzarella; Edoardo Botteri; Anthony Matthews; Elena Gatti; Davide Di Salvatore; Vincenzo Bagnardi; Massimo Breccia; Pau Montesinos; Teresa Bernal; Cristina Gil; Timothy J Ley; Miguel Sanz; Krishnan Bhaskaran; Francesco Lo Coco; Pier Giuseppe Pelicci
Journal:  Haematologica       Date:  2019-09-12       Impact factor: 9.941

10.  Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.

Authors:  Li Zhang; Yao Zou; Yumei Chen; Ye Guo; Wenyu Yang; Xiaojuan Chen; Shuchun Wang; Xiaoming Liu; Min Ruan; Jiayuan Zhang; Tianfeng Liu; Fang Liu; Benquan Qi; Wenbin An; Yuanyuan Ren; Lixian Chang; Xiaofan Zhu
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430
View more
  1 in total

Review 1.  Pediatric Acute Myeloid Leukemia-Past, Present, and Future.

Authors:  Dirk Reinhardt; Evangelia Antoniou; Katharina Waack
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.